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journal homepage: www.eu- openscie nce.e uropea nurology.comCOVID-19 has challenged us to become more dynamic than
ever before in assuming new responsibilities in patient care
and serving our community via new means. Through all the
upheaval, a consistent beacon of hope can be found in our
community’s reinvigorated commitment to issues beyond
the genitourinary tract and overall health [11]. As we
continue to advance in our fight against COVID-19, we must
reflect on how these lessons learned may transcend the
pandemic and be leveraged to improve future practice.
In many respects, the extent to which we have been
asked to work hand-in-hand with general practitioners,
hospitalists, and other specialty services actually bears
resemblance to the means by which current European
Association of Urology (EAU) and American Urological
Association (AUA) guidelines ask us to approach lower
urinary tract symptoms (LUTS) in routine practice. Multiple
LUTS have been increasingly described as clinically relevant
predictors, markers, and central features of serious medical
conditions, such that best-practice management often
requires a multidisciplinary treatment plan and medical
disease optimization [1,2]. The importance of “nonurologic”
causes of LUTS is particularly evident in the case of nocturia,
which is prognostic of all-cause mortality and has been
identified as a hallmark of several systemic cardiovascular,
respiratory, renal, hepatic, endocrine, neurologic, and
immunologic disease states [3].
Long before beginning to receive attention as a
standalone entity, LUTS were most relevant in major
urology consensus guidelines as the clinical manifestation
of common genitourinary abnormalities such as benign
prostatic hyperplasia (BPH). The first major rendition of the* Corresponding author. Department of Urology, SUNY Downstate Health S
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“chronic conditions, such as hypertension or diabetes, have
been related to clinical BPH” [4]. However, the document
subsequently downplayed the possibility of a causal
relationship, stating, “but given the frequent occurrence
of these conditions in ageing men, a large proportion of
patients can be expected to suffer from such an association.”
Consistently, recommendations regarding diagnosis were
squarely centered on the genitourinary tract, and the
seemingly benign nature of LUTS provided the basis for
watchful waiting as a first-line management strategy:
“BPH affects quality rather than the quantity of life. The
risk of serious sequelae following a watchful waiting
policy is small. The only related morbidities are the
development of acute urinary retention or impairment of
renal function.”
The first AUA guidelines on BPH were published in
2003 and similarly described medical disease to be most
relevant as a clinical distractor and implicit grounds for
exclusion [5]:
“The challenge in patients with LUTS is to establish that
the symptoms are due to BPH. Nonprostatic causes of
symptoms can be excluded in a significant number of
patients on the basis of a medical history, physical
examination, and urinalysis. ( . . . ) A medical history
should be taken to identify other causes of voiding
dysfunction or comorbidities that may complicate
treatment.”ciences University, Brooklyn, NY 11203, USA. Tel. +1 718 2702554;
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EAU Guidelines on Conservative Treatment of Non-neurogenic
Male LUTS [6]. As the authors explained themselves,
contemporary scientific advances had provided the nidus
for this change in nomenclature:
“The latest knowledge and developments suggest that
not all bladder symptoms of elderly men are necessarily
linked to the prostate (BPH-LUTS) ( . . . ) This more
distinguished view of LUTS has led to re-formation of the
content and panel of the EAU guidelines.”
The intricate relationship between LUTS and systemic
disease has been further expanded in the most recent major
revisions to the EAU (2019) and AUA (2018) guidelines.
Current EAU guidelines contend that causes unrelated to
lower urinary tract dysfunction “have to be considered in all
cases” [2]. This concept has been operationalized in the
current International Continence Society Consensus state-
ment on the diagnosis and treatment of nocturia, which
details a holistic, patient-oriented diagnostic and therapeu-
tic algorithm for nocturia that may be generalized to other
LUTS [7]. Likewise, the AUA guidelines now feature the
complex etiology of LUTS as a pressing future research
direction [8]:
“There are enormous gaps in knowledge and, therefore,
ensuing opportunities for discovery. These include but
are not limited to many unanswered questions, such as
the role of inflammation, metabolic dysfunction, obesity,
and environmental factors in etiology, as well as the role
of behavior modification, self-management, and evolv-
ing therapeutic algorithms in both the prevention and
progression of disease.”
Taken together, the past two decades of EAU and AUA
guidelines on BPH reflect a fundamental shift in the way in
which contemporary evidence on LUTS has been interpreted,
synthesized, and disseminated by the primary urological
professional societies in Europe and the USA. This theme is
likewise salient in current evidence on urinary incontinence
and overactive bladder syndrome [9]. Once most relevant as a
clinical distractor in the evaluation of other genitourinary
abnormalities, medical disease has become a central tenet in
the evaluation and management of LUTS.
The importance of a comprehensive medical assessment
was emphasized in a recent systematic review of nocturia
by the EAU guidelines panel for male LUTS, which affirmed
that “the symptom of nocturia is an important one, since
there may be a significant medical cause, [and] potentially
an opportunity to screen for undiagnosed or suboptimally-
managed disease . . . ” [10]. Nocturia and other LUTS, as
potential harbingers of serious systemic disease, thus
provide another unique platform from which urologistsmay tangibly improve overall health and survival. There-
fore, a comprehensive medical examination, often warrant-
ing referral to another specialty and a multimodal care plan,
must now be considered a fundamental responsibility in the
management of a patient presenting with LUTS. To this end,
even in the wake of COVID-19, our reinvigorated spirit of
interdisciplinary collaboration must not be forgotten.
Conflicts of interest: Karel Everaert is a consultant and lecturer for
Medtronic and Ferring and has received institutional grants from
Allergan, Ferring, Astellas, and Medtronic. Alan J. Wein has served as an
advisor/consultant for Bulkamid, Medtronic, Serenity, Urovant, and
Velicept. Jeffrey P. Weiss is a consultant for Ferring and the Institute for
Bladder and Prostate Research. Thomas F. Monaghan and Jason M. Lazar
have nothing to disclose.
References
[1] Weiss J, Blaivas J. Urological symptoms of nonurologic origin.
American Urological Association update series: lesson 17. Linthi-
cum, MD: American Urological Association; 2002.
[2] Gravas S, Cornu J, Gacci M, et al. Management of non-neurogenic
male lower urinary tract symptoms (LUTS), incl. benign prostatic
obstruction (BPO). Arnhem, The Netherlands: European Association
of Urology; 2019.
[3] Cornu JN, Abrams P, Chapple CR, et al. A contemporary assessment
of nocturia: definition, epidemiology, pathophysiology, and man-
agement—a systematic review and meta-analysis. Eur Urol
2012;62:877–90.
[4] De la Rosette J, Perachino M, Thomas D, et al. Guidelines on benign
prostatic hyperplasia.. Arnhem, The Netherlands: European Associ-
ation of Urology; 2001.
[5] Roehrborn CG, McConnell JD, Barry MJ, et al. Guideline on the
management of benign prostatic hyperplasia (BPH). Linthicum,
MD: American Urological Association; 2003.
[6] Oelke M, Bachmann A, Descazeaud A, et al. Guidelines on conser-
vative treatment of non-neurogenic male LUTS. Arnhem,
The Netherlands: European Association of Urology; 2010.
[7] Everaert K, Herve F, Bosch R, et al. International Continence Society
consensus on the diagnosis and treatment of nocturia. Neurourol
Urodyn 2019;38:478–98.
[8] Foster HE, Barry MJ, Ghandi MC, et al. Benign prostatic hyperplasia:
surgical management of benign prostatic hyperplasia/lower urinary
tract symptoms. Linthicum, MD: American Urological Association;
2018, (amended 2019).
[9] Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of
non-neurogenic overactive bladder (OAB) in adults: an AUA/SUFU
guideline. Linthicum, MD: American Urological Association; 2012,
(amended 2019).
[10] Sakalis VI, Karavitakis M, Bedretdinova D, et al. Medical treatment
of nocturia in men with lower urinary tract symptoms: systematic
review by the European Association of Urology guidelines panel for
male lower urinary tract symptoms. Eur Urol 2017;72:757–69.
[11] Khusid JA, Sullivan JE, Esdaille AR, et al. SUNY Downstate Health
Sciences University Urology Team. Role of the Urologist During a
Pandemic: Early Experience in Practicing on the Front Lines in
Brooklyn, New York. Eur Urol 2020;78(1):e36–7. http://dx.doi.
org/10.1016/j.eururo.2020.04.024.
